REG - Renalytix PLC - Services contract with Joslin and Pharma Partner

RenalytixAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250729:nRSc8895Sa&default-theme=true

RNS Number : 8895S  Renalytix PLC  29 July 2025

Renalytix plc

("Renalytix" or the "Company")

 

Services contract with Joslin Diabetes Center and Major Pharma Partner

 

Renalytix expands pharma services for proteomics research and precision
diagnostics development

 

LONDON and NEW YORK, 29 July 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY),
a precision medicine diagnostics company, with kidneyintelX.dkd, the only
FDA-approved and Medicare reimbursed prognostic test to support early-stage
risk assessment in chronic kidney disease, announces that it has been
contracted to undertake a biomarker research and precision diagnostics
programme with Joslin Diabetes Center ("JDC") and a leading global
pharmaceutical company.  This development work has begun on a completed phase
3 GLP-1 agonist clinical trial targeting management of blood sugar levels in
people with Type 2 diabetes.

 

Under the contract, Renalytix will examine the clinical utility of 21
circulating proteins that are most strongly associated with progression to
end-stage kidney disease.  This panel of proteins, when measured on the Olink
Proximity Extension Assay (PEA) proteomics platform, are collectively referred
to as the Joslin Kidney Panel (JKP(TM)). The data generated will inform
strategy for future drug clinical trials. Results are expected to be published
in 2026.

 

Renalytix has agreed exclusive access with JDC for the use of the proprietary
JKP(TM) which has been shown to have a wide range of potential applications
including prognosis of Cardiovascular and Kidney disease progression,
prediction of drug response and monitoring of impact of care.

 

Renalytix believes this proprietary technology significantly expands the
Renaltyix services offering to Pharma for Proteomics Biomarker Research and
Development and has substantial services revenue value from supporting current
and next generation pharmaceutical drug development and commercial programmes
in Cardiovascular, Renal and Metabolic Diseases (CVRM).

 

Fergus Fleming, Chief Technology Officer of Renalytix said: "Today's
announcement is a significant milestone in our journey to bring precision
diagnostics solutions to patients with chronic disease and is built on years
of world class research from the laboratory of our long-time collaborator,
Prof. Andrzej Krolewski at the Joslin Diabetes Center. Having developed and
implemented kidneyintelX.dkd as the first precision diagnostic test in chronic
kidney disease and having seen the golden age of new therapies coming to
market in recent years, we now set our sights on the next wave of innovation
where we believe the role of novel biomarkers in clinical practice will be
pivotal to delivering the best possible outcomes for patients with Diabetes
and its complications including Kidney and Cardiovascular disease. This
expansion of our multi-modal precision medicine platform will accelerate the
rate of data generation with Pharma and Academic partners necessary to fuel
product development and clinical adoption of precision medicine in Chronic
Disease."

 

For further information, please contact:

 

 Renalytix plc                                     www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                             Via Walbrook PR

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)                   Tel: +44 (0)20 3470 0470
 Jeff Keating / David Hignell (Corporate Finance)

 Vadim Alexandre (Corporate Broking)

 Oberon Capital (Joint Broker)                     Tel: +44 (0)20 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                               Tel: 020 7933 8780 or renalytix@walbrookpr.com
 Paul McManus / Alice Woodings                     Mob: 07980 541 893 / 07407 804 654

 

About Renalytix (www.renalytix.com (http://www.renalytix.com) )

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

KidneyIntelX is based on technology developed by Mount Sinai faculty and
licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and
equity owners in the Company. In addition, the Icahn School of Medicine at
Mount Sinai has equity ownership in Renalytix.

 

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes
treatment and research. Part of Beth Israel Lahey Health, Joslin is dedicated
to finding a cure for diabetes and ensuring that people with diabetes live
long, healthy lives. Joslin develops and disseminates innovative patient
therapies and scientific discoveries throughout the world. A part of Beth
Israel Lahey Health, Joslin is affiliated with Harvard Medical School and one
of only 18 NIH-designated Diabetes Research Centers in the United States.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUWSRRVBUBUUR